Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK) and preliminary
efficacy of XOMA 052 in subjects with active Type 2 Diabetes Mellitus (T2D).
IV administration of XOMA 052 is likely to improve glycemic control in subjects with T2D by
blocking certain receptors.